- Home
- AGIO vs STR Comparison
AGIO vs STR Comparison
Compare AGIO & STR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- STR
- Stock Information
- Founded
- AGIO 2007
- STR 2016
- Country
- AGIO United States
- STR United States
- Employees
- AGIO N/A
- STR N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- STR Oil & Gas Production
- Sector
- AGIO Health Care
- STR Energy
- Exchange
- AGIO Nasdaq
- STR Nasdaq
- Market Cap
- AGIO 1.4B
- STR 1.2B
- IPO Year
- AGIO 2013
- STR N/A
- Fundamental
- Price
- AGIO $27.66
- STR $17.06
- Analyst Decision
- AGIO Buy
- STR Buy
- Analyst Count
- AGIO 8
- STR 6
- Target Price
- AGIO $56.57
- STR $27.00
- AVG Volume (30 Days)
- AGIO 745.1K
- STR 939.2K
- Earning Date
- AGIO 05-01-2025
- STR 05-07-2025
- Dividend Yield
- AGIO N/A
- STR 8.22%
- EPS Growth
- AGIO N/A
- STR N/A
- EPS
- AGIO 11.64
- STR 0.49
- Revenue
- AGIO $36,498,000.00
- STR $624,414,000.00
- Revenue This Year
- AGIO $41.13
- STR N/A
- Revenue Next Year
- AGIO $234.96
- STR $2.83
- P/E Ratio
- AGIO $2.38
- STR $34.82
- Revenue Growth
- AGIO 36.07
- STR 5.23
- 52 Week Low
- AGIO $23.42
- STR $14.58
- 52 Week High
- AGIO $62.58
- STR $25.64
- Technical
- Relative Strength Index (RSI)
- AGIO 44.94
- STR 44.60
- Support Level
- AGIO $26.87
- STR $14.86
- Resistance Level
- AGIO $28.24
- STR $16.18
- Average True Range (ATR)
- AGIO 1.94
- STR 1.06
- MACD
- AGIO 0.22
- STR -0.10
- Stochastic Oscillator
- AGIO 66.15
- STR 43.36
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.